Shopping Cart
Research status · Hepatology · PRP
PRP and liver regeneration: What research currently shows for fibrosis and cirrhosis
The liver can regenerate remarkably well after limited injury. With persistent inflammation, metabolic disease, alcohol exposure, medication toxicity or viral infection, however, scar tissue may progressively replace functional tissue. Researchers are therefore examining whether platelet-rich plasma could support regenerative signalling. The concept is biologically plausible, but it has not been clinically proven.
Status: August 2026
Important: not an established treatment
PRP is not a recognised standard treatment for liver fibrosis or cirrhosis. There is no validated protocol and no robust clinical efficacy evidence. The current evidence base consists almost entirely of cell and animal experiments.
Evidence compass
Preclinical signalsavailable
Clinical evidencevery limited
Standard treatmentno
01 · PRP
What is PRP?
PRP is produced from blood by centrifugation, creating a plasma fraction with an increased platelet concentration. Platelets store biologically active mediators including PDGF, VEGF, EGF, IGF-1, HGF and TGF-β1. These signals can influence cell proliferation, angiogenesis, immune responses and extracellular-matrix remodelling. PRP is not a uniform product: platelet concentration, leukocyte content, anticoagulant, activation and processing vary substantially, making studies difficult to compare.
From laboratory to clinic
01
Laboratory02
Animal model03
Pilot study×
Routine carenot reached02 · SIGNAL PATHWAYS
Why might platelets affect liver regeneration?
Liver regeneration depends on coordinated interactions between hepatocytes, endothelial cells, immune cells, hepatic stellate cells and multiple signalling pathways. Platelet-based preparations may influence several of these levels at the same time.
Cell regeneration
HGF, EGF, VEGF and IGF-1 are involved in regenerative pathways. Experimental models have reported increased cell proliferation and reduced pro-apoptotic activity. This does not show that PRP can restore a severely damaged human liver.
Fibrotic pathways
In some animal models, platelet-based treatments were associated with lower fibrosis-related markers such as TGF-β1 and α-SMA. This does not mean that PRP can reverse established cirrhosis. Platelets also contain TGF-β1, so effects may differ according to the biological environment.
Inflammation and oxidative stress
Some experiments reported lower inflammatory markers, increased antioxidant activity and altered macrophage responses. Results depended strongly on the injury model, timing and composition of the preparation.
Microcirculation
VEGF and other mediators can influence endothelial cells and new vascular structures. Whether this translates into a clinically relevant improvement in organ function in humans remains unknown.
03 · PRECLINICAL
What do animal studies show?
A 2026 systematic review evaluated 14 experimental studies involving toxic, surgical, parasitic, cholestatic or radiation-induced liver injury. Many reported lower liver enzymes, less oxidative stress, reduced collagen deposition and improved histology. The evidence remains limited: studies used not only conventional PRP, but also platelet lysates, supernatants, gels, washed platelets or combinations with stem cells. Processing, dose and cellular composition were often incompletely documented. Results were not consistently positive, including in a rabbit model after major liver resection.
04 · EV RESEARCH
PRP-derived vesicles: promising, but a separate research approach
In 2024, extracellular vesicles derived from PRP were studied in a mouse model of cirrhosis. Several laboratory and tissue markers improved, with changes in regenerative genes, fibrotic pathways and macrophage activity. Isolated vesicles are not ordinary PRP. Their production, characterisation and regulatory status are substantially more complex, so these findings cannot be treated as evidence for a conventional PRP injection.
05 · HUMAN DATA
What is known from human studies?
Robust clinical trials of autologous PRP for fibrosis or cirrhosis are lacking. A frequently cited 2013 Japanese pilot study enrolled ten people with chronic liver disease, cirrhosis and thrombocytopenia who received weekly platelet concentrates; only six were included in the final analysis. Some laboratory parameters improved, while adverse reactions also occurred. Crucially, this was an allogeneic platelet concentrate, not autologous PRP. Without a control group or meaningful clinical endpoints, it is not evidence of PRP efficacy.
06 · CLINICAL LIMITS
Why is cirrhosis particularly difficult?
- Platelet count and function are often altered in advanced cirrhosis.
- Coagulation is complex; bleeding and thrombotic risks may coexist.
- Producing a sufficiently standardised autologous preparation may be difficult.
- Dose, composition, activation and route of administration remain unresolved.
07 · STANDARD OF CARE
Not an alternative to causal treatment
Chronic liver diseases have different causes. Established management targets the underlying cause and the complications of disease. PRP is not part of recommended standard care and must not delay diagnosis, guideline-based treatment or assessment at a hepatology centre.
08 · STUDY DESIGN
What would a meaningful clinical trial need to answer?
- Exact characterisation of the PRP preparation and cellular composition
- Clear separation of early fibrosis, compensated cirrhosis and decompensated cirrhosis
- Control groups, randomisation and predefined safety criteria
- Clinically relevant endpoints rather than laboratory changes alone
- Documentation of fibrosis, liver function, decompensation, quality of life and adverse events
09 · VERDICT
Evidence-based assessment
PRP and other platelet-based preparations show biologically interesting effects in experimental models. The gap between a positive animal experiment and an effective treatment for human liver disease remains large. At present, PRP for liver fibrosis and cirrhosis is a preclinical research approach, not an established therapy.
10 · REFERENCES
Selected sources
1
Systematic review of platelet-based preparations in liver injury (2026)Open source ↗
2Experimental model after major liver resection (2025)Open source ↗
3PRP-derived extracellular vesicles in a mouse cirrhosis model (2024)Open source ↗
4Pilot study of platelet transfusion in chronic liver disease (2013)Open source ↗
5EASL guideline on metabolic dysfunction-associated steatotic liver diseaseOpen source ↗
PRPMED
Further links
This article is intended for professional information. It does not describe an approved standard treatment and does not recommend the use of PRP for liver disease.